Log In
BCIQ
Print this Print this
 

Canmab, biosimilar trastuzumab

  Manage Alerts
Collapse Summary General Information
Company Biocon Ltd.
DescriptionBiosimilar to trastuzumab
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionBinds HER2/neu; Antibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentMarketed
Standard IndicationBreast cancer
Indication DetailsTreat HER2-positive metastatic breast cancer
Regulatory Designation
PartnerMylan N.V.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today